Prior to joining CIC, Chris worked at C4X Discovery, an AIM-listed drug discovery biotechnology company, as part of the Corporate Strategy and Development team, where he focused on identifying and sourcing opportunities for in-licensing, collaboration and internal development.
Chris also brings a background in strategy consulting and due diligence support, working in L.E.K. Consulting’s Life Sciences practice across the UK and US.
Chris holds an MA in Medical Sciences from the University of Cambridge. Chris currently acts as Board Observer on behalf of CIC for: Carrick Therapeutics, Epitopea, Exvastat, Microbiotica and Mosaic Therapeutics.
Fighting aggressive cancers
Harnessing the power of the microbiome
Targeted molecular cancer therapies created by breaking down cancer’s complexity